Bristol-Myers Squibb Co. (BMY) News

Bristol-Myers Squibb Co. (BMY): $59.16

0.38 (+0.65%)

POWR Rating

Component Grades








Filter BMY News Items

BMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BMY News Highlights

  • For BMY, its 30 day story count is now at 22.
  • Over the past 19 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about BMY are DRUG, ABBV and ACT.

Latest BMY News From Around the Web

Below are the latest news stories about BRISTOL MYERS SQUIBB CO that investors may wish to consider to help them evaluate BMY as an investment opportunity.

UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination

BeiGene and Swiss drugmaker Novartis have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months. BeiGene will regain full global rights to the drug, tislelizumab, or Tevimbra, with no royalty payments due to Novartis, which will continue to manufacture it. Novartis had paid $650 million to gain those rights in 2021.

Yahoo | September 19, 2023

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed at $58.58 in the latest trading session, marking a -0.76% move from the prior day.

Yahoo | September 18, 2023

FDA approves GSK's unique myelofibrosis treatment Ojjaara

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.

Yahoo | September 18, 2023

Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

Yahoo | September 17, 2023

The 3 Most Undervalued Pharma Stocks to Buy in September 2023

Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now.

Chris Markoch on InvestorPlace | September 14, 2023

Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates

Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.

Yahoo | September 14, 2023

Bristol Myers plans to double experimental treatments to expand research pipeline

The drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies that target immune system disorders and different types of cancer. The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition. Bristol and partner Pfizer's blood thinner Eliquis was also on the list of 10 drugs that will be subject to the first-ever price negotiations by the U.S. Medicare health program.

Yahoo | September 14, 2023

Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day

PRINCETON, N.J., September 14, 2023--Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day

Yahoo | September 14, 2023

The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.

Roz Brewer stepped down from leading Walgreens, and the next CEO is a tough choice.

Will Ashworth on InvestorPlace | September 13, 2023

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

Yahoo | September 13, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!